Tomocube
Tomocube develops holotomography microscopy systems and AI-powered image analysis software that enable label-free, non-invasive 3D quantitative imaging of live cells and transparent materials. The company serves academic researchers, pharmaceutical and biotech firms, semiconductor manufacturers, and emerging clinical applications globally.
- Company typePublic
- Founded2015
- HeadquartersDaejeon, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tomocube does
Tomocube, Inc. is a South Korea-based, KOSDAQ-listed (since November 2024) developer and manufacturer of holotomography (HT) microscopy systems and supporting AI-driven image analysis software. Founded in 2015 in Daejeon by KAIST physics professor YongKeun (Paul) Park, the company commercializes a label-free, non-invasive 3D imaging technique that reconstructs refractive index distributions from LED-based incoherent illumination to produce quantitative tomograms of live cells, tissues, and transparent industrial materials without staining or sample destruction. Its product portfolio spans the HT-X1 family of bioimaging instruments (the flagship HT-X1 Plus with integrated epifluorescence and spinning disk confocal modalities, the HT-X1, and the compact HT-X1 mini), the industrial metrology systems HT-T1 (transmission) and HT-R1 (reflection), and the TomoAnalysis software suite with AI-based segmentation and quantification modules.
The company's commercial model centers on hardware system sales as the primary revenue driver, complemented by a growing recurring revenue base from TomoAnalysis software subscriptions/licenses, HT-ready 96-well plates and accessories (consumables), and professional services. Pricing is quote-based across all product lines with multi-year contracts, and go-to-market is executed through wholly-owned direct sales subsidiaries in Korea (headquarters), the United States (San Diego, profitable in 2025 with approximately 4 billion KRW revenue), and Germany (Langen, established June 2025 with 8.6 billion KRW in its first year), plus dedicated sales leadership for Greater China appointed in April 2026. The company invests approximately 46% of revenue in R&D and holds more than 90 patents covering its core technology and AI applications.
Tomocube serves four primary verticals: academic and life science research institutions (cell biology, organoids, regenerative medicine, immunology, LLPS, stem cell research), pharmaceutical and biotechnology companies (drug discovery, organoid screening, cell therapy QC), semiconductor and display manufacturers using the Precision Division for non-destructive 3D metrology (launched September 2025), and emerging clinical applications such as IVF embryo assessment. Named customers and partners include KAIST, Johns Hopkins University, Institut Gustave Roussy, the NCI-led Human Tumor Atlas Network (HTAN), University of Lausanne, Okomera (droplet microfluidics integration), CrestOptics (spinning disk confocal integration), and an unnamed global pharmaceutical company under a joint development agreement. As of FY2025, Tomocube reported revenue of 113 billion KRW (up 90.4% year-over-year), with overseas revenue contributing 75.9% of the total and the company achieving its first quarterly operating profit in Q4 2025.
Tomocube firmographics
Firmographics- Name
- Tomocube
- Legal name
- Tomocube, Inc.
- Website
- https://tomocube.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Tomocube develops holotomography microscopy systems and AI-powered image analysis software that enable label-free, non-invasive 3D quantitative imaging of live cells and transparent materials. The company serves academic researchers, pharmaceutical and biotech firms, semiconductor manufacturers, and emerging clinical applications globally.
- Ownership category
- akta.pro rank
Tomocube industry classification
Industry- Product category
- 3D Holotomography Microscopy and Bioimaging Systems
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
Keywords
Where Tomocube is headquartered
LocationHeadquarters
- HQ city
- Daejeon
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
Tomocube business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Holotomography Imaging Systems: Sale of HT series hardware systems (HT-X1 Plus, HT-X1, HT-X1 mini, HT-T1, HT-R1) for life science research and industrial precision metrology. Primary revenue driver representing majority of company sales.
- TomoAnalysis Software: Image analysis software with AI-powered quantification and visualization. Subscription or license model for ongoing software updates and support. Recurring revenue stream growing as installed base expands.
- Accessories and Consumables: HT-ready 96 well plates, accessories, and consumables for HT systems. Expanding recurring revenue base through consumables sales.
- Professional Services: Technical support, training, installation, and customer development services. Part of comprehensive one-stop support system.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Full product lineup from entry-level to flagship systems |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Tomocube product offering
Product offeringCore offering
Tomocube designs, manufactures, and sells holotomography (HT) 3D imaging systems and accompanying AI-powered analysis software for label-free, non-invasive imaging of live cells and transparent industrial materials. The company's commercial portfolio spans life-science microscopy systems (HT-X1 Plus, HT-X1, HT-X1 mini) with the TomoAnalysis software suite, and industrial precision-metrology systems (HT-T1, HT-R1) for non-destructive semiconductor, glass substrate, and display inspection.
Differentiator
Problem solved
Functional benefit
Brands
- HT-X1 Plus: Flagship holotomography system with 4x larger field of view, 6x faster scanning, integrated epifluorescence and spinning disk confocal modalities, and AI-powered TomoAnalysis for high-throughput 3D bioimaging.
- HT-X1
- HT-X1 mini
- TomoAnalysis
- HT-T1
- HT-R1
- Precision Division
Products and services
- HT-X1 Plus Flagship holotomography live-cell 3D imaging system integrating second-generation holotomography with multimodal imaging (epifluorescence and spinning disk confocal). Designed for organoid, stem cell research, drug discovery, and regenerative medicine applications with automated AI-powered quantification.
- HT-X1 Second-generation holotomography microscope using incoherent LED light source with single-beam technique for mechanically stable, high-contrast label-free 3D imaging of live cells. Includes 40x 0.95 NA objective and integrated 4-channel fluorescence engine with multi-well plate compatibility.
- HT-X1 mini Compact, accessible holotomography platform at one-third the size and weight of the flagship model. Modular design with upgrade options including stage-top incubator, 3-channel fluorescence, laser autofocus, and additional wavelengths, designed to broaden adoption among smaller labs, startups, educational institutions, and clinics.
- TomoAnalysis AI-powered 3D image visualization and analysis software suite for holotomography data. Uses module-based data processing with AI-based analysis models for cellular and subcellular structure quantification, with capabilities like the Data Manager Combine function for 4D analysis merging multiple datasets.
- HT-T1 Transmission Holotomography Transmission-based holotomography system for non-destructive 3D inspection of transparent industrial materials including glass substrates, waveguides, and optical elements. Delivers 161nm lateral resolution, 1.298μm axial resolution, and 10^-4 refractive index sensitivity.
- HT-R1 Reflection Holotomography World's first reflection-based holotomography system for non-destructive 3D inspection of opaque and transparent industrial samples including wafers, display panels, and semiconductor packages. Provides 130nm lateral resolution, 0.294μm axial resolution, and 0.1nm surface sensitivity.
Quantifiable outcome
- Full 96-well plate scanned in under 30 minutes with HT-X1 Plus
- +5 more outcomes
Companies that use Tomocube
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Tomocube technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability9 records
Feature6 records
Tomocube partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- OkomeracoreCollaboration on integrated droplet-based microfluidics and holotomography workflow for patient-derived organoid drug screening. Okomera's droplet-based organoid culture combined with Tomocube's HT-X1 enables label-free, quantitative monitoring of chemotherapy response in patient-derived tumoroids. Demonstrates synergy between Tomocube imaging and Okomera's high-throughput screening platform.
- CrestOptics S.p.A.coreStrategic collaboration to provide next-generation multimodal imaging platform. HT-X1 Plus integrates CrestOptics' spinning disk confocal technology with Tomocube's holotomography, creating first commercially available spinning-disk confocal holotomographic instrument. Enables high-resolution label-free 3D imaging combined with fluorescence-based detection for advanced biophysical imaging applications.
- Daejeon TechnoparkminorDaejeon Technopark signed trilateral MOU with Daejeon Metropolitan Government and BioCentury to connect local biotech companies with global investors and pharmaceutical partners. Tomocube among 11 Daejeon-based companies featured in investor relations pitching session alongside Eli Lilly, SBC Group, and Temasek. Part of Daejeon's positioning as global biotech investment hub.
- Global Pharmaceutical Company (unnamed)coreJoint development agreement for non-bio (industrial precision) applications of holotomography technology. Collaboration with a National Institutes of Health agency on Organoid research standardization.
Scale indicators7 records
Recent moves10 records
Expansion highlights6 records
Tomocube competitors and assessment
Company assessmentBroad incumbents
- Carl Zeiss Microscopy: Dominant incumbent in life science microscopy offering confocal, super-resolution, and light-sheet systems with deep installed base and global service. Comparable as a broad microscopy competitor whose R&D resources could incorporate label-free 3D imaging capabilities.
- Leica Microsystems (Danaher): Major microscopy brand under Danaher's life sciences portfolio offering confocal, widefield, and advanced 3D imaging systems. Directly competes for the same academic and pharma imaging budgets as Tomocube with bundled multi-modal platforms.
- Nikon Instruments: Established Japanese microscopy and imaging provider serving life science, clinical, and industrial customers. Comparable as a multi-modality microscope vendor that competes for capital equipment budgets at universities and pharma.
- Evident (formerly Olympus Scientific Solutions): Major microscopy and life science imaging brand (formerly Olympus) offering confocal and live-cell imaging systems. Comparable as a broad microscopy incumbent competing for the same cell biology and pharma imaging use cases as Tomocube.
- Bruker: Global scientific instruments company with a significant microscopy business covering super-resolution, AFM, and nano-analysis. Comparable as a research tools incumbent whose broad portfolio targets overlapping academic and biopharma customers.
- KLA Corporation: Global leader in semiconductor process control and yield management with dominant position in wafer inspection and metrology. Comparable as the incumbent Tomocube's Precision Division must compete against in semiconductor packaging and TGV inspection.
Direct peers
- Nanolive: Swiss-based startup offering label-free 3D live cell imaging using holotomography-like technology. The most direct comparable to Tomocube's life science product line, targeting similar academic and pharma customers with a competing label-free imaging approach.
- Phase Holographic Imaging (PHI): Swedish company developing quantitative holographic imaging for label-free cell analysis and time-lapse monitoring. Direct competitor in the holotomography/holographic imaging niche with similar life science research applications.
Emerging players
- CytoSMART (Axion BioSystems): Dutch live-cell imaging company providing compact, accessible microscopy systems for cell culture monitoring. Comparable as an emerging player focused on democratizing live-cell imaging for smaller labs and high-throughput workflows.
Regional players
- Park Systems: Korean nano-metrology company and AFM leader with overlapping customer base in academic and industrial research. Comparable as a Korean-headquartered precision instruments peer that shares the same domestic market and some academic/government customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Tomocube social profiles
Digital presenceTomocube compliance and trust
Trust signalCompliance2 records
Tomocube financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tomocube leadership team
Management profileNumber of profiles
Profiles6 records
Tomocube subsidiaries and ownership
Company hierarchySubsidiaries2 records
Tomocube funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tomocube M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tomocube
What does Tomocube do?
Tomocube designs, manufactures, and sells holotomography (HT) 3D imaging systems and accompanying AI-powered analysis software for label-free, non-invasive imaging of live cells and transparent industrial materials. The company's commercial portfolio spans life-science microscopy systems (HT-X1 Plus, HT-X1, HT-X1 mini) with the TomoAnalysis software suite, and industrial precision-metrology systems (HT-T1, HT-R1) for non-destructive semiconductor, glass substrate, and display inspection.
Is Tomocube a public or private company?
Tomocube is a public company. It is classified as public and is currently operating.
When was Tomocube founded?
Tomocube was founded in 2015. It employs 51 to 100 people.
Where is Tomocube based?
Tomocube is headquartered in Daejeon, South Korea, in the Asia region.
How does Tomocube make money?
Four revenue lines are on record. Holotomography Imaging Systems are the primary driver. The others are tomoAnalysis Software, accessories and Consumables and professional Services.
Who are Tomocube's main competitors?
Broad incumbents on record are Carl Zeiss Microscopy, Leica Microsystems (Danaher), Nikon Instruments, Evident (formerly Olympus Scientific Solutions), Bruker and KLA Corporation. Direct peers are Nanolive and Phase Holographic Imaging (PHI). CytoSMART (Axion BioSystems) is listed as an emerging player. Park Systems is listed as a regional player.
Does Tomocube have an API?
No public API is recorded for Tomocube.
What industry is Tomocube in?
Tomocube's product category is 3D Holotomography Microscopy and Bioimaging Systems. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334516 and its SIC code is 3826.